These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237 [TBL] [Abstract][Full Text] [Related]
3. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310 [TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
10. Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Nishida T; Tsuneyama K; Fujimoto M; Nomoto K; Hayashi S; Miwa S; Nakajima T; Nakanishi Y; Sasaki Y; Suzuki W; Iizuka S; Nagata M; Shimada T; Aburada M; Shimada Y; Imura J Lab Invest; 2013 Feb; 93(2):230-41. PubMed ID: 23212097 [TBL] [Abstract][Full Text] [Related]
11. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Soejima Y; Fukusato T World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive study of the interplay between immunological and metabolic factors in hepatic steatosis. Banerjee A; Das D; Mukherjee S; Maji BK Int Immunopharmacol; 2024 May; 133():112091. PubMed ID: 38657500 [TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Dietrich P; Hellerbrand C Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181 [TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]
15. Iron overload in nonalcoholic steatohepatitis. Fujita N; Takei Y Adv Clin Chem; 2011; 55():105-32. PubMed ID: 22126026 [TBL] [Abstract][Full Text] [Related]
16. The epidemiology of nonalcoholic fatty liver disease in adults. Clark JM J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768 [TBL] [Abstract][Full Text] [Related]
17. Role of liver biopsy in nonalcoholic fatty liver disease. Nalbantoglu IL; Brunt EM World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076 [TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pydyn N; Miękus K; Jura J; Kotlinowski J Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853 [TBL] [Abstract][Full Text] [Related]
20. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. Zhou JH; Cai JJ; She ZG; Li HL World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]